Compare CMCT & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | OGEN |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.6M |
| IPO Year | N/A | N/A |
| Metric | CMCT | OGEN |
|---|---|---|
| Price | $3.10 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 53.3K |
| Earning Date | 03-06-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,028,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.56 | $0.74 |
| 52 Week High | $25.75 | $18.90 |
| Indicator | CMCT | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 58.62 |
| Support Level | $3.15 | $0.81 |
| Resistance Level | $3.59 | $0.91 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 0.78 | 100.00 |
Creative Media & Community Trust Corp is formed to invest in, own, and operate Class A and creative office investments in improving urban communities throughout the United States. It operates through segments such as office, hotel and multifamily properties and lending. The Office segment includes rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment relates to operations of hotel properties whereas, the lending segment refers to income from the yield and other related fee income earned on its loans receivable. The lending segment includes income recognized from the sale of government guaranteed portion of loans receivable, income from the yield on its loans receivable and other related fee income earned.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.